Belén Garijo/LinkedIn
Apr 28, 2025, 12:34
Belén Garijo: Merck Group acquires SpringWorks Therapeutics for €3 billion
Belén Garijo, Chair of the Executive Board and CEO of Merck Group, shared a post on LinkedIn:
“Today marks a historic milestone in our journey of sustainable growth and innovation at Merck Group. We’re excited to announce the signing of a definitive agreement to acquire SpringWorks Therapeutics, a U.S.-based commercial-stage biopharmaceutical company, for approximately €3 billion. By combining our Healthcare portfolio, expertise, and resources with those of SpringWorks, we aim to address a significant area of unmet need for patients worldwide.
This news represents our largest planned Merck Healthcare acquisition in almost two decades. It strongly reinforces our resilience, significantly strengthens our growth strategy, and endorses Merck’s long-term commitment to the biopharma sector. A big thanks to the entire team who made this happen, especially given current volatility and uncertainty across our world. This is a big achievement that speaks volumes of the competence and determination of our Merck teams!”
Belén Garijo announced that Merck Group has signed a definitive agreement to acquire SpringWorks Therapeutics for approximately €3 billion. The acquisition, the company’s largest healthcare deal in nearly twenty years, is aimed at addressing unmet patient needs and strengthening Merck’s growth strategy and biopharma commitment.
More posts featuring Belén Garijo.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 28, 2025, 12:34
Apr 28, 2025, 12:34
Apr 28, 2025, 12:23
Apr 28, 2025, 12:21
Apr 28, 2025, 12:17